More Syntara Limited news
Syntara LimitedASX: SNT

Pharmaxis Releases Positive Results of Phase 1 Clinical Tria

Nov 14, 2018 at 9:49 PM EST · Issued by Syntara Limited

Filed with ASX · Nov 14, 2018 at 9:49 PM EST · 2 pages · English

On 6ix: 6ix.com/news/pharmaxis-releases-positive-results-of-phase-1-clinical-tria

Syntara Limited on 6ix

Earlier from Syntara

  • Positive Phase 1 Results of Phase 1 Study - LOXL2 InhibitorOct 10, 2018
  • FDA Factory Approval and Relaunch of Aridol in US MarketAug 14, 2018
  • Capital Raising PresentationAug 6, 2018
  • Trading Halt Announcement - System UpgradeAug 5, 2018
  • Quarterly Shareholder Update - June 2018Jul 26, 2018

Later from Syntara

  • LOX Inhibitor Program for Pancreatic Cancer Phase 1 ReadyNov 19, 2018
  • Pharmaxis AGM - CEO PresentationNov 22, 2018
  • Pharmaxis Announces First Relaunch Sales of Aridol in USADec 12, 2018
  • Pharmaxis announces resubmission of bronchitol nda in usaDec 19, 2018
  • Pharmaxis Announces LOXL2 Program Phase 2 ReadyJan 16, 2019
All Syntara news releases↗

Follow Syntara into a list and get an email when it puts out news.

Follow Syntara
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer